Basic Research in Cardiology

, Volume 72, Issue 5, pp 454–463 | Cite as

Studies on isoprenaline-induced myocardial lesions 1. Quantitative evaluation by Mercurascan uptake

  • E. Faltová
  • M. Mráz
  • L. Kronrád
  • L. Protivová
  • J. Šedivý
Original Contributions

Summary

For the quantitative evaluation of myocardial damage induced by isoprenaline (ISO) a method based on the uptake of203Hg-labelled Mercurascan (MSC) in the heart was used.

The increase of myocardial uptake of MSC in ISO-treated rats over control values was very rapid and might be directly proportional to the number of damaged myocardial cells actually present in the heart.

MSC-uptake method of myocardial damage evaluation was more sensitive and precise than other methods tested (macroscopic evaluation according toRona, increase of heart weight).

Different modifications of MSC-uptake test may be selected in relation to experimental conditions. MSC test is especially useful for evaluation of early myocardial lesions induced by small doses of ISO (0.01 mg/kg).

Keywords

Public Health Quantitative Evaluation Small Dose Myocardial Cell Isoprenalin 

Untersuchungen über isoprenalinbedingte Myokardläsionen

Zusammenfassung

Für die quantitative Bewertung der Myokardschädigung durch Isoprenalin (ISO) wurde eine Methode benutzt, die auf der Aufnahme von203Hg-markiertem Mercurascan (MSC) in das Herz beruht.

Der Anstieg der myokardialen Aufnahme von MSC bei isoprenalinbehandelten Ratten über Kontrollwerte war sehr rasch und dürfte direkt proportional zur Anzahl der tatsächlich geschädigten Myokardzellen im Herzen sein.

Die Methode der MSC-Aufnahme für die Bewertung der Myokardläsionen war empfindlicher und genauer als andere getestete Methoden (makroskopische Bewertung nachRona, Anstieg des Herzgewichts).

Verschiedene Modifikationen des MSC-Aufnahmetests stehen zur Wahl in Abhängigkeit von den experimentellen Bedingungen. Der MSC-Test ist besonders nützlich für die Bewertung früher myokardialer Läsionen, die durch kleine Dosen von Isoprenalin (0,01 mg/kg) hervorgerufen wurden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boutet, M., I. Hüttner, G. Rona: Permeability alteration of sarcolemmal membrane in catecholamine-induced cardiac muscle cell injury. Lab. Invest.34, 482–488 (1976).PubMedGoogle Scholar
  2. 2.
    Faltová, E., M. Mráz, K. Kronrád, J. Pilný, J. Šedivý: Some aspects of quantitative evaluation of isoprenaline induced lesions of myocardium. Proc. Internat. Symp. Adaptability of Cardiac muscle (Prague 1974) in press.Google Scholar
  3. 3.
    Hearse, D. J., S. M. Humphrey, E. B. Chain: Abrupt reoxygenation of anoxic potassium — arrested perfused rat heart. A study of myocardial enzyme release. J. Mol. Cell. Cardiol.5, 395–407 (1973).CrossRefPubMedGoogle Scholar
  4. 4.
    Hearse, D. J., S. M. Humphrey, W. G. Nayler, A. Slade, D. Border: Ultrastructural damage associated with reoxygenation of the anoxic myocardium. J. Mol. Cell. Cardiol.7, 315–324 (1975).CrossRefPubMedGoogle Scholar
  5. 5.
    Jennings, R. B., Ch. E. Ganote, K. A. Reimer: Ischemic tissue injury. Amer. J. Pathol.81, 179–198 (1975).Google Scholar
  6. 6.
    Kronrád, L., J. Ratuský, P. Málek, B. Vavrejn, J. Kolc: Preparation of some mercury derivatives of fluorescein labelled with isotopes197Hg and203Hg. III. Recoil-labelling of derivatives. J. Label. Cpds.6, 326–332 (1970).Google Scholar
  7. 7.
    Kučerová, V., J. Kolc, P. Málek: Studies on the therapeutic use of Mercurascan, part III.: influence of Mercurascan on some metabolic changes in experimental myocardial ischemia in dogs. Section I: Energetic and ionic metabolism. Int. J. Clin. Pharmacol. Ther Tox.11, 40–51 (1975).Google Scholar
  8. 8.
    Leszkovszky, G. P., Gy. Gál: Observations on isoprenaline-induced myocardial necroses. J. Pharm. Pharmacol.19, 226–230 (1967).PubMedGoogle Scholar
  9. 9.
    Magnusson, G., E. Hansson: Myocardial necrosis in the rat. A comparison between Isoprenaline, Orciprenaline, Salbutamol and Terbutaline. Cardiology58, 174 (1973).PubMedGoogle Scholar
  10. 10.
    Málek, P., J. Ratuský, B. Vavrejn, L. Kronrád, J. Kolc: Ischemia detecting radioactive substances for scanning cardiac and skeletal muscle. Nature214, 1130–1131 (1967).PubMedGoogle Scholar
  11. 11.
    Málek, P., B. Vavrejn, J. Ratuský, L. Kronrád, J. Kolc: Geschwindigkeit der selektiven Akkumulation von Mercurascan203 im geschädigten Muskel und im ischämischen Myokard. Experientia33, 649–651 (1967).Google Scholar
  12. 12.
    Málek, P., J. Kolc, M. Vrána, Z. Blažek: Effect of mercury derivatives of fluorescein on the fibrillation threshold in experimental myocardial infarction. Experientia27, 273 (1971).PubMedGoogle Scholar
  13. 13.
    Meltzer, H. Y., A. Guschwan: Effect of Isoproterenol on rat plasma creatine phosphokinase activity. Arch. Int. Pharmacodyn. Ther.194, 141–146 (1971).PubMedGoogle Scholar
  14. 14.
    Mrhová, O., J. Kolc, P. Málek: Studies on the therapeutic use of Mercurascan, part III.: Influence of Mercurascan on some metabolic changes in experimental myocardial ischemia in dogs. Section II.: Enzymes. Int. J. Clin. Pharmacol. Ther. Tox.11, 52–57 (1975).Google Scholar
  15. 15.
    Pilný, J., M. Mráz, E. Faltová, J. Šedivý: unpublished results.Google Scholar
  16. 16.
    Ratuský, J., L. Kronrád, P. Málek, B. Vavrejn, J. Kolc: Preparation of some mercury derivatives of fluorescein labelled with isotopes197Hg or203Hg. I. Study of preparation methods. J. Label. Cpds.6, 311–318 (1970).Google Scholar
  17. 17.
    Rona, G., C. I. Chappel, T. Balazs, R. Gaudry: An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Arch. Pathol.67, 443–455 (1959).Google Scholar
  18. 18.
    Shell, W. E., J. K. Kjekshus, B. E. Sobel: Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum phosphokinase activity. J. Clin. Invest.50, 2614–2625 (1971).PubMedGoogle Scholar
  19. 19.
    Stanton, H. C., A. Schwarz: Effects of a hydrazine monoamine oxidase inhibitor (Phenelzine) on isoproterenol-induced myocardiopathies in the rat. J. Pharmacol. Exp. Ther.157, 649–658 (1967).PubMedGoogle Scholar
  20. 20.
    Zbinden, G.: Beeinflussung der experimentellen, durch Isoproterenol hervorgerufenen Myokardnekrose durch Aminooxydasehemmer, gefäßerweiternde und tranquilisierende Arzneimittel. Arzneimittelforschg.12, 635 (1962).Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag 1977

Authors and Affiliations

  • E. Faltová
    • 1
    • 2
    • 3
  • M. Mráz
    • 1
    • 2
    • 3
  • L. Kronrád
    • 1
    • 2
    • 3
  • L. Protivová
    • 1
    • 2
    • 3
  • J. Šedivý
    • 1
    • 2
    • 3
  1. 1.Institute of PhysiologyCzechoslovak Academy of SciencesPragueCzechoslovakia
  2. 2.Department of Pharmacology, Faculty of General MedicineCharles UniversityPragueCzechoslovakia
  3. 3.Nuclear Research Institute Rež near PragueCzechoslovakia

Personalised recommendations